A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women.
Schalkwijk S, Ter Heine R, Colbers AC. et al
Clin Pharmacokinet. 2018 Mar 8.
Abstract

Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy.
Chappell CA, Lamorde M, Nakalema S, et al
AIDS. 2017 Jul 7.
Abstract

Antiretroviral therapy with efavirenz accentuates pregnancy-associated reduction of dihydroartemisinin-piperaquine exposure during malaria chemoprevention.
Kajubi R, Huang L, Jagannathan P, Chamankhah N, et al
Clin Pharmacol Ther. 2017 Feb 10.
Abstract

Unintended pregnancies observed with combined use of the levonorgestrel contraceptive implant and efavirenz-based antiretroviral therapy: a three-arm pharmacokinetic evaluation over 48 weeks.
Scarsi KK, Darin KM, Nakalema S, et al
Clin Infect Dis. 2015 Dec 8.
Abstract

Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study.
Patel RC, Onono M, Gandhi M,  et al
Lancet HIV. 2015 Nov;2(11):e474-82
Abstract

Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.
Olagunju A, Bolaji O, Amara A,  et al
Clin Pharmacol Ther. 2015 Mar;97(3):298-306.
Abstract

Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.
Olagunju A, Bolaji O, Amara A, et al
Clin Pharmacol Ther. 2014 Nov 29.
Abstract

Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.
Cohan D, Natureeba P, Koss CA,  et al 
AIDS. 2015 Jan 14;29(2):183-91
Abstract

Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS
Olagunju A, Bolaji OO, Amara A, et al
J Antimicrob Chemother. 2014 Oct 17
Abstract

Risk Factors for Preterm Birth among HIV-Infected Pregnant Ugandan Women Randomized to Lopinavir/ritonavir- or Efavirenz-based Antiretroviral Therapy.
Koss CA, Natureeba P, Plenty A,  et al
J Acquir Immune Defic Syndr. 2014 Jul 26
Abstract

Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis co-infection.
Dooley KE, Denti P, Martinson N, Cohn S,  et al
J Infect Dis. 2014 Jul 31.
Abstract

Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis.
Ford N, Mofenson L, Shubber Z,
AIDS. 2014 Mar;28 Suppl 2:S123-31.
Abstract